# IXNO Cold Outreach Email Templates

> **Usage**: Customize the bracketed `[PLACEHOLDER]` fields before sending.
> All emails reference the attached Technical Whitepaper (`IXNO_MODULE_WHITEPAPER.md`) and Clinical Impact assets.

---

## Template A: Tech Integration (iFlytek / Huawei / Large EMR vendors)

**Subject**: [IXNO] Bridging the Critical Care Logic Gap — 85k-Validated TCM Field Dynamics

Dear [Dr./Mr./Ms. Last Name],

I've been following [Company]'s progress in [voice AI / multimodal diagnostics / EMR infrastructure] — the breadth of [your] deployment across [X hospitals / Y provinces] is genuinely impressive.

However, one gap persists industry-wide: **deterministic clinical reasoning for critical care deterioration**. LLMs hallucinate. Rule-based CDSS systems lack pathophysiological depth. And every ICU director we speak to tells the same story: "The patient crashes before the numbers move."

We've built something different.

IXNO is a **field-dynamics-based paradigm** that models disease progression as state vector evolution — V (Yin/Blood), λ (Yang/Qi), and a collapse rate dλ/dt. It doesn't "predict" in the statistical sense; it **detects the moment pathophysiology crosses a threshold** — typically 12 hours before SOFA or lactate register the change.

**Key metrics (validated on 85,242 MIMIC-III ICU stays):**
- aHR 2.30 for Heat Collapse (Re Jue) detection
- 12-hour lead time vs conventional SOFA-based monitoring
- Zero hallucination (deterministic computation, no LLM in clinical path)

I believe [Company]'s [voice platform / CDSS product / hospital network] and IXNO's core modules (Classifier M03 + Frame M02) have a natural complementarity. I'd love to schedule a 30-minute technical deep-dive next week.

Please find our Technical Whitepaper attached. Clinical impact visuals at: [GitHub Repository URL]/docs/assets/

Warm regards,
IXNO Technologies
amyicf79@gmail.com

---

## Template B: Hospital Deployment (ICU Directors / CMOs)

**Subject**: [IXNO] Seeing the Unseen — Detecting Heat Collapse 12 Hours Before Lactate Rises

Dear Dr. [Last Name],

If you've ever watched a septic patient "look fine" at morning rounds — lactate 2.2, SOFA stable — only to crash by evening, then you understand why we built IXNO.

The problem isn't monitoring frequency. It's **what** you're monitoring. Lactate is a downstream metabolite. SOFA is an aggregate score. Neither captures the moment pathophysiology **crosses a threshold**.

Our M01-Field Engine models each patient's V-λ state vector in real time. When dλ/dt breaches −0.015/hr, we fire a Re Jue (Heat Collapse) alert — aHR 2.30 across 85,242 ICU stays. In the attached case study, this alert fired **12 hours before SOFA increased by ≥2 points** and **while lactate was still 2.2 mmol/L**.

**What this means for your ICU:**
- Earlier vasopressor initiation (evidence-based timing, not "gut feel")
- Reduced ICU mortality through pre-emptive intervention
- Integration with existing monitors (no new hardware required)

I'd be happy to walk your team through a demo using de-identified case data. We can also provide a 30-day risk-free pilot deployment.

Attachments: Technical Whitepaper + Clinical Impact Comparison Chart + Single-Case Trajectory Report.

Best,
IXNO Technologies
amyicf79@gmail.com

---

## Template C: Health Startup / Wellness App

**Subject**: [IXNO] Frame M02 — The Compliance Skeleton Your TCM App is Missing

Hi [First Name],

Love what you're building with [App Name]. The TCM wellness space is growing fast, but there's a recurring challenge: **safety at scale**.

When your app suggests a formula with Fu Zi (附子), who checks that the patient's eGFR isn't below 30? When a user combines your wellness recommendation with their prescribed anticoagulant, who catches the interaction?

That's IXNO-Frame (M02). It's a **safety skeleton** — a lightweight API that sits between your recommendation engine and your user. It doesn't replace your formula logic. It just ensures nothing dangerous reaches the user.

**Frame M02 checks:**
- Dose ceilings (e.g., Fu Zi ≤ 9g without monitored setting)
- Contraindications (e.g., 雷公藤 & eGFR < 30)
- Herb-drug interactions (e.g., Danshen & Warfarin)
- Cold/Heat mismatch (e.g., Huang Lian in a cold-pattern patient)

Pricing is revenue-share based (5–10%), so it aligns with your growth. No upfront cost. We only succeed when your users are safe and your app is trusted.

Would you be open to a 15-minute call to discuss integration?

Cheers,
IXNO Technologies
amyicf79@gmail.com

---

## Template D: Academic / Research Collaboration

**Subject**: [IXNO] TCM-SHARD Module-00 — Open Empirical Validation for Your Research

Dear Professor [Last Name],

I came across your recent work on [TCM diagnosis standardization / sepsis biomarker discovery / integrative medicine] and was struck by the alignment with our open validation layer, TCM-SHARD.

TCM-SHARD (Module-00 of the IXNO ecosystem) is a fully open, MIMIC-III-validated empirical framework that bridges critical care data and TCM syndrome differentiation. It's released under MIT license — free for academic use with citation.

**What's available:**
- 13-anchor PCA space with Bootstrap-validated loading matrices
- 30-case blinded verification dataset (with manual adjudication)
- Full survival analysis pipeline (KM curves, Cox regression with Schoenfeld residuals)
- aHR 2.30 for Heat Collapse detection

We're actively seeking academic collaborators for:
- External validation on non-MIMIC datasets
- Integration with TCM clinical trial endpoints
- Joint grant applications (NSFC / NIH CAM)

Would you be interested in a collaboration discussion? I'd be happy to share the full technical dossier.

Kind regards,
IXNO Technologies
amyicf79@gmail.com
